Key highlights

  • Alterity Therapeutics Ltd (ASX:ATH) touched a 52-week low during the 20 October 2026 session and closed at $0.27, down 15.63%.
  • Alterity ended FY2026 with A$37.3 million in cash and reported alignment with the FDA on the design of a pivotal Phase 3 trial of ATH434.
  • The net loss after tax rose 92.6% to A$23.4 million for the year ended 30 June 2026.

Alterity Therapeutics Ltd (ASX:ATH) touched a 52-week low during the Trading session on 20 October 2026 and closed at $0.27, down 15.63%. Alterity’s latest document covered here is its Annual Report for the year ended 30 June 2026, which does not carry a release date on the copy reviewed. No latest announcement has driven the share price move, so the announcement is described below on its own terms.

About Alterity Therapeutics

Alterity Therapeutics Limited is a clinical-stage biotechnology company listed on the ASX and, through American Depositary Shares under the symbol ATHE, on the Nasdaq Capital Market. It is developing ATH434, a candidate for multiple system atrophy (MSA), and operates a drug discovery platform targeting neurological diseases.

Clinical and regulatory progress

According to the annual report, Alterity and the US Food and Drug Administration reached alignment on the core design elements of a single pivotal Phase 3 trial of ATH434 in MSA, including approximately 200 patients, modified UMSARS Part I as the primary endpoint and a 50 mg dose given twice daily. The FDA agreed to use the 11-item UMSARS Part I as the primary endpoint, which was also the key clinical endpoint in the Phase 2 study.

In the Phase 2 study, the 50 mg cohort showed an approximately 46% relative treatment effect at week 52, which the company described as clinically meaningful and statistically significant. The report notes that Phase 3 results may not replicate Phase 2, and that preparation work on science and Manufacturing continues.

FY2026 financial results

Alterity recorded Revenue of A$1,716,656 for the year ended 30 June 2026, compared with A$446,291, which consisted mainly of interest on bank accounts. The net loss after tax for the year rose 92.6% to A$23,400,949. The company’s cash position was A$37,317,962 at 30 June 2026, compared with A$33,158,642 a year earlier, and it subsequently received a further A$3.98 million.

No Dividend was paid or declared, and none is recommended. The report states that the group has incurred losses and relies on Equity raisings, and that it successfully raised new equity during the year.

Sector backdrop

Neurodegenerative disease programs face high clinical failure rates, long timelines and substantial funding needs, and a single pivotal Phase 3 trial represents a major cost. Multiple system atrophy is a rare, rapidly progressive disease with no approved disease-modifying treatment, according to the company.

Clinical-stage biotech companies typically fund development through equity capital, which can dilute existing shareholders.

Risks shareholders should weigh

Phase 3 has not started, and the company acknowledges that a positive Phase 2 result does not guarantee the same outcome in a larger trial. It will need substantial additional funding for a pivotal trial of about 200 patients, and the report lists risks around manufacturing dependence and Nasdaq compliance.

The net loss almost doubled year on year, and the company has no product revenue. Share price movements for clinical-stage companies can be sharp.

What’s next

Items to watch include the start of the Phase 3 trial, further regulatory feedback, funding arrangements for the trial and the company’s quarterly cash reports.